Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon242
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?145
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing140
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer123
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?119
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?117
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms114
Acknowledgement to Reviewers 2021112
Editorial Board93
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?90
Editorial Board87
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis78
Editorial Board75
Current state of play for HPV-positive oropharyngeal cancers71
Editorial Board67
Local control strategies for management of NSCLC with oligoprogressive disease66
Editorial Board63
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer62
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review60
Editorial Board58
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers55
Editorial Board52
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)51
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations50
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy49
Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review48
Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors45
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in44
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis44
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer43
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)42
NTRK gene fusion testing and management in lung cancer41
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma41
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice40
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group40
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias39
Treatment landscape of metastatic pancreatic cancer39
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies39
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials39
0.066957950592041